Key Figures

All figures are given in millions of € according to the IFRS, unless otherwise specified 2015 2014 2013
restated
2013 2012 2011
Order intake, sales revenue and earnings
Order intake 1,172.7 929.2 819.6 912.3 866.8 749.5
Sales revenue 1,114.8 891.2 791.6 887.3 845.7 733.1
Underlying EBITDA1) 263.2 186.8 162.3 172.6 161.1 136.6
Underlying EBITDA1) as % of sales revenue 23.6 21.0 20.5 19.5 19.0 18.6
Relevant net profit for continuing operations2) 107.4 66.1 59.2  
Relevant net profit2) 107.4 73.7 64.8 64.8 63.0 52.8
Research and development costs 52.5 43.63) 47.7 53.8 49.0 44.3
Financial data per share
Earnings per share for continuing operations2)
per ordinary share in €
6.29 3.87 3.46
per preference share in €
6.31 3.89 3.48
Earnings per share2)
per ordinary share in €
6.29 4.31 3.79 3.79 3.69 3.09
per preference share in €
6.31 4.33 3.81 3.81 3.71 3.11
Dividends
per ordinary share in €
1.504) 1.06 1.00 1.00 0.94 0.80
per preference share in €
1.524) 1.08 1.02 1.02 0.96 0.82
Balance Sheet
Balance sheet total 1,437.2 1,272.4 1,181.3 1,176.6 1,070.9 960.2
Equity 644.8 497.1 450.3 450.3 404.4 366.1
Equity ratio in % 44.9 39.1 38.1 38.3 37.8 38.1
Financials
Capital expenditures (excluding financial assets and goodwill) 113.1 80.9 60.6 62.9 74.2 51.8
Capital expenditures as a % of sales 10.1 9.1 7.7 7.1 8.8 7.1
Amortization | depreciation 58.9 52.7 45.8 47.7 40.6 32.8
Net cash flow from operating activities 124.4 129.7 97.0 103.3 53.2 79.0
Net debt 344.0 335.65) 345.15) 345.1 303.8 264.8
Ratio of net debt to underlying EBITDA 1.3 1.75) 2.05) 2.0 1.9 1.9
Total number of employees as of December 31 6,185 5,611 5,1586) 5,8636) 5,491 4,8877)

1) Underlying = adjusted for extraordinary items

2) After non-controlling interest, adjusted for extraordinary items as well as non-cash amortization, and based on the normalized financial result as well as the corresponding tax effects for each of these items

3) Restated

4) Amounts suggested by the Supervisory Board and the Executive Board of Sartorius AG

5) Including discontinued operation

6) Excluding TAP Biosystems

7) Excluding Biohit